Personalized medicine takes on tough melanoma
NCT ID NCT02645149
First seen Nov 19, 2025 · Last updated May 25, 2026 · Updated 17 times
Summary
This study looked at 216 people with advanced melanoma that didn't have common BRAF or NRAS mutations and had stopped responding to standard therapy. Researchers analyzed each person's tumor DNA to find specific mutations and then gave them a drug designed to target that mutation. The goal was to see if this personalized approach could shrink tumors or slow the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2260, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.